



Corrigendum: Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics

Maurizio Pompili*

Department of Neuroscience, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Maurizio Pompili
maurizio.pompili@uniroma1.it

Specialty section:

This article was submitted to
Mood and Anxiety Disorders,
a section of the journal
Frontiers in Psychiatry

Received: 05 February 2020

Accepted: 06 February 2020

Published: 27 February 2020

Citation:

Pompili M (2020) Corrigendum:
Adding Suicide Prevention to the Triple
Advantages of Injectable Long-Acting
Second-Generation Antipsychotics.
Front. Psychiatry 11:101.
doi: 10.3389/fpsy.2020.00101

Keywords: suicide, treatment outcome, relapse, adherence, prevention

A Corrigendum on

Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics

By Pompili M. *Front. Psychiatry* 10:931. doi: 10.3389/fpsy.2019.00931

The author wishes to disclose that in the last two years he has lectured and served on advisory board honoraria or engaged in clinical trial activities with Angelini, Lundbeck, Janssen, Otsuka, and Allergan.

The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Pompili. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.